AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Nuvation Bio Inc. (NUVB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.27

-0.03 (-1.30%)

At close: Feb 20, 2025, 3:59 PM

2.27

0.22%

After-hours: Feb 20, 2025, 07:00 PM EST

undefined% (undefined)

Bid	2.25
Market Cap	762.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.18
PE Ratio (ttm)	-1.04
Forward PE	n/a
Analyst	Buy

Ask	2.44
Volume	604,315
Avg. Volume (20D)	2,438,679
Open	2.31
Previous Close	2.30
Day's Range	2.25 - 2.32
52-Week Range	1.67 - 4.16
Beta	undefined

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiat...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 26, 2020

Employees 203

Stock Exchange NYSE

Ticker Symbol NUVB

Website https://www.nuvationbio.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 341.50% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+14.44%

Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription

6 months ago

-5.36%

Nuvation Bio shares are trading lower. The company reported Q2 financial results.

News

1 week ago · seekingalpha.com

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Appl...

2 weeks ago · businesswire.com

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access...

1 month ago · businesswire.com

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, Pre...

1 month ago · businesswire.com

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the ...

2 months ago · businesswire.com

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hun...